The DOI matches its Crossref record; 21 of the 23 references it cites were found in a registry or an index.
Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study
Abstract
Background Antidepressant discontinuation syndrome (ADS) frequently occurs in patients who undergo an abrupt discontinuation of their antidepressant medication. Methods We evaluated 25 consecutive outpatients with depression who discontinued their use of escitalopram. The presence of ADS was evaluated according to the Antidepressants Discontinuation Syndrome checklist. Results Antidepressant discontinuation syndrome was observed in 14 of 25 patients. Frequent symptoms were dizziness (44%), muscle tension (44%), chills (44%), confusion or trouble concentrating (40%), amnesia (28%), and crying (28%). The treatment doses and plasma concentrations of escitalopram were significantly higher in patients with ADS than in patients without ADS. No group differences were observed regarding age, sex, or duration of escitalopram treatment before the discontinuation. Conclusions These findings suggest that a higher dose and lower clearance of escitalopram lead to a higher risk of ADS. Very slow tapering is recommended for all patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Higher SSRI plasma levels before cessation 58 and just after cessation 59 predict increased withdrawal symptoms.”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [58]
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D., Woods, R., Lawson, R., & Taylor, D. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 285
The Clinical Pharmacokinetics of Escitalopram
Rao, N. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746040-00002 · Cited by 256
Kurose, K., Sugiyama, E., & Saito, Y. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-11-rv-111 · Cited by 234
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
Cited by
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
“Another study, evaluating 25 outpatients treated with escitalopram, found 14 (56%) experienced withdrawal reactions, with higher dose and lower clearance leading to higher risk of withdrawal (Yasui-Furukori et al., 2016).”
BackgroundTapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
(2025) · doi:10.1038/s41380-024-02782-4 · Cited by 32
“The half-life of drugs does not show a simple dose-dependent relationship with the incidence of withdrawal symptoms in short-term studies (8-12 weeks), and the pooled estimate is robust regardless of whether the approach taken was through RCTs or observational studies (including face-to-face and online survey studies).”
InfluentialEichentopf, L., Hiemke, C., Conca, A., Engelmann, J., Gerlach, M., Havemann‐Reinecke, U., Hefner, G., Florio, V., Kuzin, M. I., Lieb, K., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.972141 · Cited by 25
Jauhar, S., & Hayes, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.01.025 · Cited by 23
Metadata
- Authors
- Yasui-Furukori, N., Hashimoto, K., Tsuchimine, S., Tomita, T., Sugawara, N., Ishioka, M., & Nakamura, K.
- Affiliations
- Hirosaki University (JP)
- Venue
- Clinical Neuropharmacology
- Published
- 2016-05
- Volume
- 39
- Issue
- 3
- Pages
- 125-127
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2385864113
- Cited by
- 13
- References
- 23
- Citations by year
- 2025: 2 · 2024: 3 · 2022: 2 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 1
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- escitalopram, antidepressant discontinuation syndrome, depression, antidepressant tapering, plasma drug concentration, drug clearance, dizziness, chills
- MeSH terms
- Adult, Depression, Female, Humans, Japan, Male, Middle Aged, Outpatients, Psychiatric Status Rating Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study. https://app.cochat.ai/papers/10.1097/wnf.0000000000000139
- The paper
- Yasui-Furukori, N., Hashimoto, K., Tsuchimine, S., Tomita, T., Sugawara, N., Ishioka, M., & Nakamura, K. (2016). Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0000000000000139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.